Top 10 Small-Cap Biotech Catalyst Changes This Week

Week of 2026-06-01. This public report highlights selected clinical catalyst timing, filing, and runway signals across undercovered biotech companies.

Top 10 Catalyst Watch Items

1. IGC - Clinical Trial Completion

IGC Pharma Inc has a public catalyst watch item for IGC-AD1-Active in Alzheimer Disease | Agitation,Psychomotor | Care Giving Burden | NPS | Aggression. Expected timing: 2026-03-30.

Public view: Clinical Trial on Agitation in Alzheimer's Dementia primary/completion milestone expected by 2026-03-30.

Pro view later: binary risk, cash runway, source confidence, trial design context, and source-linked analyst note.

2. OSTX - Clinical Trial Completion

OS Therapies Inc has a public catalyst watch item for PD-L1 t-haNK in Locally Advanced Solid Tumor | Metastatic Cancer | Solid Tumor. Expected timing: 2026-03-30.

Public view: QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers primary/completion milestone expected by 2026-03-30.

Pro view later: binary risk, cash runway, source confidence, trial design context, and source-linked analyst note.

3. XLO - Clinical Trial Completion

Xilio Therapeutics Inc has a public catalyst watch item for vilastobart (XTX101) in Advanced Solid Tumor. Expected timing: 2026-03-30.

Public view: Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors primary/completion milestone expected by 2026-03-30.

Pro view later: binary risk, cash runway, source confidence, trial design context, and source-linked analyst note.

4. OTLK - Clinical Trial Completion

Outlook Therapeutics Inc has a public catalyst watch item for Behavioral Health Home Hospital in Psychosis | Anxiety | Depression | Behavioral and Psychiatric Symptoms of Dementia. Expected timing: 2026-04-30.

Public view: Acute Psychiatric Care at Home for Lower-risk Patients With Acute Psychiatric Illness Who Require Inpatient Care primary/completion milestone expected by 2026-04-30.

Pro view later: binary risk, cash runway, source confidence, trial design context, and source-linked analyst note.

5. AZTR - Clinical Trial Completion

Azitra Inc has a public catalyst watch item for ATR12-351 in Netherton Syndrome. Expected timing: 2026-06-01.

Public view: Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome primary/completion milestone expected by 2026-06-01.

Pro view later: binary risk, cash runway, source confidence, trial design context, and source-linked analyst note.

6. RKTO - Clinical Trial Completion

Rocket One Inc has a public catalyst watch item for Rocatinlimab in Atopic Dermatitis. Expected timing: 2026-06-22.

Public view: A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) primary/completion milestone expected by 2026-06-22.

Pro view later: binary risk, cash runway, source confidence, trial design context, and source-linked analyst note.

7. BCAB - Clinical Trial Completion

BioAtla Inc has a public catalyst watch item for Durvalumab in Ovarian Cancer. Expected timing: 2026-06-30.

Public view: Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer primary/completion milestone expected by 2026-06-30.

Pro view later: binary risk, cash runway, source confidence, trial design context, and source-linked analyst note.

8. LGVN - Clinical Trial Completion

Longeveron Inc has a public catalyst watch item for Lomecel-B medicinal signaling cells in Hypoplastic Left Heart Syndrome. Expected timing: 2026-06-30.

Public view: Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial. primary/completion milestone expected by 2026-06-30.

Pro view later: binary risk, cash runway, source confidence, trial design context, and source-linked analyst note.

9. MBIO - Clinical Trial Completion

Mustang Bio Inc has a public catalyst watch item for cyclophosphamide in Adult Acute Myeloid Leukemia in Remission | Acute Biphenotypic Leukemia | Early Relapse of Acute Myeloid Leukemia | Late Relapse of Acute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm | Acute Myeloid Leukemia | Adult Acute Lymphoblastic Leukemia | Interleukin-3 Receptor Subunit Alpha Positive | Minimal Residual Disease | Refractory Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia. Expected timing: 2026-08-06.

Public view: Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm primary/completion milestone expected by 2026-08-06.

Pro view later: binary risk, cash runway, source confidence, trial design context, and source-linked analyst note.

10. BOLD - Clinical Trial Completion

Boundless Bio Inc has a public catalyst watch item for BBI-355 in Triple Negative Breast Cancer (TNBC) | High Grade Serous Ovarian Carcinoma | High Grade Endometrial Carcinoma | Anogenital Cancer | Head and Neck (HNSCC) | Cutaneous Squamous Cell Carcinoma (CSCC) | Cervical Squamous Cell Carcinoma | ER+ Breast Cancer | Leiomyosarcoma (LMS) | Undifferentiated Pleomorphic Sarcoma (UPS) | Pancreatic Cancer Metastatic | Small Cell Lung Cancer. Expected timing: 2026-09-30.

Public view: Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications primary/completion milestone expected by 2026-09-30.

Pro view later: binary risk, cash runway, source confidence, trial design context, and source-linked analyst note.

What To Monitor Next

Watch for ClinicalTrials.gov date changes, new SEC filings, financing updates, and company-guided readout windows.

This page is for informational and educational purposes only and does not constitute investment advice.